Tumor gene diagnosis marker combined with carcinoembryonic antigen and application of tumor gene diagnosis marker

Abstract

The invention discloses a tumor gene diagnosis marker combined with carcinoembryonic antigen and application of the tumor gene diagnosis marker. By combining miR-609 and the carcinoembryonic antigen, the colorectal cancer screening accuracy is improved, and the defect that the accuracy is not high when the carcinoembryonic antigen is independently used for colorectal cancer screening is overcome. Therefore, the miR-609 can be combined with the carcinoembryonic antigen to prepare a serum detection kit for early diagnosis of colorectal cancer.

Description

technical field [0001] The invention belongs to the field of disease diagnosis, and in particular relates to a tumor gene diagnostic marker combined with carcinoembryonic antigen and its application. Background technique [0002] Colorectal cancer (CRC) is one of the most common malignant tumors worldwide. It is estimated that the age-standardized incidence rate of CRC in the world in 2020 is 19.5 / 100,000, and the mortality rate is 9.0 / 100,000. The incidence of CRC is relatively high in developed countries. In the United States, the age-standardized incidence rate of CRC in the past five years is about 38.7 / 100,000, and the mortality rate is 13.9 / 100,000. The practical experience of many countries shows that the adoption of effective colorectal cancer screening strategies can reduce the disease burden of colorectal cancer (Research Status and Reflections on Colorectal Cancer Screening Strategies, Chinese Journal of General Practice, September 2021). [0003] Carcinoembryoni...

AI Technical Summary

Problems solved by technology

[0005] However, the accuracy of CEA or AFP for

Images